All In Biotech

Drug Trial Radar · NCT00557245

Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition Within HIV-1 Discordant Couples

Parallel Comparison of Tenofovir and Emtricitabine/Tenofovir Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition Within HIV-1 Discordant Couples

Last checked: Nov 19, 2026Latest source record: Apr 19, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 4,758 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

4,758

Actual

Start

May 2008

Primary completion

Oct 2013

Study completion Oct 2013

Sponsor

Lead sponsor
University of WashingtonAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Bill and Melinda Gates Foundation
First posted
Nov 12, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Randomized, blinded, placebo-controlled trial to demonstrate if pre-exposure prophylaxis decreases HIV-1 acquisition among HIV-1 uninfected individuals within HIV-1 discordant couples.

Conditions

  • HIV-1 Infections
  • HIV Infections

Interventions

  • Tenofovir Disoproxil Fumarate (TDF)Drug

    TDF 300 mg tablet, once daily + Placebo FTC/TDF orally, once daily.

  • Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)Drug

    FTC/TDF - 200 mg tablet, once daily + Placebo TDF orally, once daily

  • PlaceboDrug

    Placebo TDF \& Placebo FTC/TDF, 1 tablet each daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of HIV-1 Seroconversion Among HIV-1 Uninfected ParticipantsTime frame: Up to 36 months
  2. Number of Participants With Serious Adverse Events (SAEs)Time frame: Up to 36 months

Locations

9 sites in 2 countries. Site status is shown where the registry gives one.

  • Moi University - Indiana University

    Eldoret, Kenya

  • CMR, Kemri-UCSF

    Kisumu, Kenya

  • Kenyatta National Hospital/University of Nairobi

    Nairobi, Kenya

  • Partners in Prevention - Thika

    Thika, Kenya

  • Kabwohe Clinical Research Center

    Bushenyi, Uganda

  • Infectious Diseases Institute

    Jinja, Uganda

  • Partners House-Infectious Disease Institute Ltd

    Kampala, Uganda

  • The AIDS Support Organization (TASO)

    Mbale, Uganda

  • The AIDS Support Organization - Tororo Field Station

    Tororo, Uganda

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.